Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (51-60 of 205) with videos related to

Pageof 21
Sort By:
Molecular Cancer Therapeutics|December 17, 2002
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistantMichelle J Frost, Petranel T Ferrao, Timothy P Hughes, et al.
Leukemia & Lymphoma|August 1, 2012
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Laura N Eadie, Verity A Saunders, Timothy P Hughes, et al.
Cancers|September 27, 2025
Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic VulnerabilitiesMolly Tolland, David M Ross, Deborah White, et al.
Cell Cycle (Georgetown, Tex.)|May 27, 2005
Inhibition of c-fms by imatinib: expanding the spectrum of treatmentAndrea L Dewar, Andrew C W Zannettino, Timothy P Hughes, et al.
Blood|January 3, 2012
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileWendy T Parker, Musei Ho, Hamish S Scott, et al.
Oncotarget|March 24, 2018
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i>Laura N Eadie, Verity A Saunders, Susan Branford, et al.
Blood|November 6, 2009
Dysregulation of bone remodeling by imatinib mesylateKate Vandyke, Stephen Fitter, Andrea L Dewar, et al.
Haematologica|October 7, 2021
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkersVaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P Hughes, et al.
Cancer|February 6, 2009
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerationsHanna Jean Khoury, François Guilhot, Timothy P Hughes, et al.
Leukemia & Lymphoma|September 21, 2013
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemiaElias J Jabbour, Timothy P Hughes, Jorge E Cortés, et al.
Pageof 21

Showing results (51-60 of 205) with videos related to

Sort By:
Pageof 21
Molecular Cancer Therapeutics|December 17, 2002
Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistantMichelle J Frost, Petranel T Ferrao, Timothy P Hughes, et al.
Leukemia & Lymphoma|August 1, 2012
Degree of kinase inhibition achieved in vitro by imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2Laura N Eadie, Verity A Saunders, Timothy P Hughes, et al.
Cancers|September 27, 2025
Lipid Storage and Therapy Resistance in Chronic Myeloid Leukaemia: A Novel Perspective on Targeting Metabolic VulnerabilitiesMolly Tolland, David M Ross, Deborah White, et al.
Cell Cycle (Georgetown, Tex.)|May 27, 2005
Inhibition of c-fms by imatinib: expanding the spectrum of treatmentAndrea L Dewar, Andrew C W Zannettino, Timothy P Hughes, et al.
Blood|January 3, 2012
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profileWendy T Parker, Musei Ho, Hamish S Scott, et al.
Oncotarget|March 24, 2018
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression <i>in vitro</i>Laura N Eadie, Verity A Saunders, Susan Branford, et al.
Blood|November 6, 2009
Dysregulation of bone remodeling by imatinib mesylateKate Vandyke, Stephen Fitter, Andrea L Dewar, et al.
Haematologica|October 7, 2021
Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkersVaidehi Krishnan, Dennis Dong Hwan Kim, Timothy P Hughes, et al.
Cancer|February 6, 2009
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerationsHanna Jean Khoury, François Guilhot, Timothy P Hughes, et al.
Leukemia & Lymphoma|September 21, 2013
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemiaElias J Jabbour, Timothy P Hughes, Jorge E Cortés, et al.
Pageof 21